Clinical Trials Logo

Clinical Trial Summary

For the present study, Investigators will examine the efficacy of active prefrontal anodal tDCS versus placebo (sham) interventions to treat WM dysfunction in schizophrenia. Investigators selected the prefrontal stimulation modality that proved most effective in enhancing high-load WM performance in single dose stimulation in healthy participants . The study employs a multi-stimulation approach, with 2 sessions per day for 5 consecutive days in the active treatment group (n=15) compared to a group that receives only sham stimulation (n=15). This preliminary approach is based upon findings of a recent study applying cathodal tDCS stimulation over left temporoparietal cortex (with left prefrontal anodal stimulation) for the treatment of persistent auditory hallucinations in schizophrenia. In a a recent study clinical benefits were maintained for at least 3 months following stimulation. In the present study, in addition to clinical outcome, researchers will evaluate whether similar improvement can be obtained with WM, EEG activity, and functional outcome (e.g., discharged from hospitalization following significant improvement or remission).


Clinical Trial Description

In a recent tDCS study investigators conducted with 41 healthy participants, researchers administered a single blind tDCS protocol that included an active unilateral DLPFC condition (2 mA for 15 minutes, anode over the left DLPFC (midpoint between F3-AF3) and cathode over the dorsal area of the superior parietal cortex (at Cz) versus a sham condition to investigate changes in online working memory function. Our preliminary tDCS results indicated gender-dependent (left enhancement in males versus females) high-load WM enhancement during active prefrontal stimulation versus sham stimulation. The observed prefrontal tDCS enhancing effect on high-load WM function indicated that left DLPFC tDCS could be implemented with SZP who suffer from inefficient left DLPFC engagement during medium to high-load WM maintenance. Given the lack of effective treatments for attenuating WM impairments and the importance of these impairments to functional outcome in schizophrenia, tDCS based cognitive-enhancing approaches may become an important new treatment method, which will consequently improve treatment and functional outcome in schizophrenia patients.The innovative nature of the study's proposed research project is that it promotes non-invasive focal (left prefrontal cortex) neuromodulation to improve cognitive functioning as well as illness severity in SZP. Most importantly, unlike antipsychotic medication that affects the entire brain circuitry and produces undesired side effects (e.g., extrapyramidal effects, weight gain, hyperlipidemia, and sexual dysfunction), the current non-invasive focal intervention is aimed at reducing specific prefrontal dysfunctions in schizophrenia by specific targeting of prefrontal electrophysiological disturbances (e.g., frontal theta synchrony) within regions known to regulate behavior and the consolidation of goal-directed information. Hypothesis Essentially, currently proposed tDCS treatment is hypothesized to improve working memory functioning and reduce symptom severity in people diagnosed with schizophrenia versus sham prefrontal tDCS (placebo).The theoretical premise for our prediction implies that effective inhibition of excessive dopaminergic mesolimbic activity (impaired in schizophrenia), could result from excitatory left-prefrontal tDCS, which has been shown to increase executive regulation of behavior in healthy individuals and people diagnosed with schizophrenia . Research plan outline For the present study, investigators will examine the efficacy of active prefrontal anodal tDCS versus placebo (sham) interventions to treat WM dysfunction in schizophrenia. Investigatros selected the prefrontal stimulation modality that proved most effective in enhancing high-load WM performance in single dose stimulation in healthy participants. A multi-stimulation approach is implemnted, with 2 sessions per day for 5 consecutive days in the active treatment group (n=15) compared to a group that receives only sham stimulation (n=15). This preliminary approach is based upon findings of a recent study applying cathodal tDCS stimulation over left temporoparietal cortex (with left prefrontal anodal stimulation) for the treatment of persistent auditory hallucinations in schizophrenia . In a recent study clinical benefits were maintained for at least 3 months following stimulation. In the present study, in addition to clinical outcome, we will evaluate whether similar improvement can be obtained with WM, EEG activity, and functional outcome (e.g., discharged from hospitalization following significant improvement or remission). In regards to efficacy, since WM is considered a core cognitive deficit in schizophrenia, investigators will monitor working memory, psychosis severity and global outcome, at baseline, immediately following tDCS intervention, and at 1, 4, and 8, 12, and 16 week intervals, following the termination the five-day treatment. Importantly, in order to show external validity of our efficacy analysis we will examine functional outcome (level of independence), six months after the termination of the tDCS intervention. Finally, since DLPFC stimulation may contribute to long-term electroencephalography (EEG) theta- rhythm functional connectivity, associated with increased large-scale theta synchronization, WM function, and episodic memory formation, investigatros will examine effects of tDCS on prefrontal versus whole-brain EEG theta activity obtained during a WM task (see verbal n-Back task), using event-related potential (ERP) and event-related spectral power (ERSP) techniques similar to those in used in recent EEG studies in schizphrenia patients. Demonstrating significant functional-connectivity EEG differences in responders versus non-responders from baseline to post-intervention measurements will significantly increase the validity of our proposed prefrontal pathophysiological mechanism as significantly impacting psychosis severity and clinical outcome in schizophrenia. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04637724
Study type Interventional
Source Herzog Hospital
Contact
Status Completed
Phase N/A
Start date November 29, 2019
Completion date September 10, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A